1. Comprehensive Introduction & Overview

The Total Artificial Heart (TAH) represents one of the most sophisticated pinnacles of mechanical circulatory support (MCS) in modern cardiovascular medicine. Unlike a Ventricular Assist Device (VAD), which typically supports only the failing left ventricle, the TAH is a biventricular replacement system. It is designed to replace both the native left and right ventricles of the heart, effectively assuming the entire workload of the systemic and pulmonary circulation.

The primary objective of a TAH is to provide a "bridge to transplant" (BTT) for patients suffering from end-stage biventricular heart failure. These patients are often critically ill, frequently in cardiogenic shock, and have reached a point where conventional pharmacological interventions or isolated left-sided mechanical support are insufficient to maintain systemic perfusion. The TAH provides immediate, high-volume blood flow, allowing for systemic recovery and stabilization while the patient awaits a donor organ.

2. Technical Specifications and Mechanisms

The most recognized and clinically utilized TAH in the modern era is the SynCardia temporary Total Artificial Heart. It is a pneumatically driven, pulsatile system that mimics the physiological function of the human heart.

Core Components

• The Pump: Two independent plastic ventricles that replace the native ventricles.
• The Valves: Four mechanical tilting-disk valves (two inflow, two outflow) that ensure unidirectional blood flow.
• The Drivelines: Two percutaneous tubes that connect the internal pump to an external driver.
• The Driver: An external console (e.g., the "Companion" or "Freedom" driver) that provides the pressurized air pulses required to actuate the pump.

Mechanism of Action

The TAH operates on a pneumatic principle. The external driver delivers precise pulses of air to the diaphragms within the artificial ventricles. As the diaphragm moves, it forces blood out of the chamber into the aorta or pulmonary artery. When the pressure is released, the chamber refills via venous return from the atria. Because it is a pulsatile system, it restores a palpable pulse to the patient, unlike continuous-flow VADs.

3. Extensive Clinical Indications & Usage

The TAH is not a first-line treatment; it is a life-saving intervention reserved for patients with severe, irreversible biventricular failure where no other option exists.

Primary Clinical Indications

1. Refractory Biventricular Failure: Patients who remain in cardiogenic shock despite maximum medical therapy and/or intra-aortic balloon pump (IABP) support.
2. Failed Left Ventricular Assist Device (LVAD): Patients who develop secondary right-sided heart failure post-LVAD implantation.
3. Congenital Heart Disease: Certain complex anatomical defects where the native anatomy cannot support a univentricular assist device.
4. Acute Myocardial Infarction: Massive infarction leading to total cardiac collapse.
5. Rejection of Cardiac Allograft: Acute, severe rejection of a previously transplanted heart where re-transplantation is not immediately feasible.

Pre-Operative Preparation

• Multidisciplinary Review: Evaluation by a heart transplant team, including cardiothoracic surgeons, cardiologists, intensivists, and social workers.
• Anatomical Assessment: High-resolution CT scans to ensure the thoracic cavity can accommodate the artificial pump (the "fit test").
• Coagulation Profiling: Establishing a baseline for heparin-induced thrombocytopenia (HIT) and other bleeding risks.
• Infection Screening: Aggressive treatment of any occult infection, as the TAH is highly susceptible to biofilm formation.

4. The Surgical Intervention: A Step-by-Step Overview

The implantation of a TAH is a major surgical procedure performed under cardiopulmonary bypass (CPB).

1. Sternotomy and Cannulation: A full median sternotomy is performed, and the patient is placed on standard cardiopulmonary bypass.
2. Excision of Native Ventricles: The surgeon excises the native left and right ventricles, leaving the native atria intact to serve as the inflow connectors.
3. Atrial Cuff Attachment: Large synthetic cuffs are sutured to the native left and right atria.
4. Inflow/Outflow Connection: The artificial ventricles are snapped into the atrial cuffs. The outflow grafts are then anastomosed to the patient’s aorta and pulmonary artery using vascular grafts.
5. Driveline Tunneling: The two pneumatic drivelines are tunneled through the abdominal wall to exit the body, providing an external connection point.
6. De-airing and Weaning: The system is meticulously de-aired to prevent embolism. The patient is gradually weaned from CPB as the TAH takes over the entire hemodynamic load.

5. Risks, Side Effects, and Contraindications

Contraindications

• Small Body Surface Area: Patients smaller than the minimum size requirements for the 50cc pump.
• Irreversible Multi-Organ Failure: If the patient has severe renal or hepatic failure that is unlikely to recover with improved cardiac output.
• Active Sepsis: High risk of device infection.
• Psychosocial Factors: Inability to manage the external driver or comply with strict follow-up requirements.

Complications

• Thromboembolism: Despite anticoagulation, the risk of stroke or peripheral embolism remains a primary concern.
• Infection: Driveline infections or endocarditis of the artificial valves.
• Bleeding: Often related to the necessary aggressive anticoagulation (Warfarin/Aspirin).
• Device Malfunction: Mechanical failure of the valves or drivelines, though rare, requires immediate surgical intervention.

6. Post-Operative Recovery and Outcomes

Recovery is typically intensive. Patients spend several days to weeks in the Cardiovascular Intensive Care Unit (CVICU).

• Anticoagulation Management: A strict regimen of Warfarin and Aspirin is mandatory to prevent thrombus formation within the device.
• Physical Therapy: Early mobilization is crucial to prevent muscle atrophy and prepare the patient for the physical demands of a future heart transplant.
• Driver Education: Patients and caregivers must undergo extensive training on how to operate, troubleshoot, and sanitize the external driver.

Typical Outcomes:
The TAH has shown excellent results in stabilizing patients who would otherwise die on the waiting list. Survival to transplant rates are generally reported between 70% and 85% in major academic centers. Improvements in quality of life are often dramatic, as systemic perfusion is restored to near-normal levels.

7. Alternative Treatments

When a patient is not a candidate for TAH, or when the condition is less severe, alternatives include:
* LVAD (Left Ventricular Assist Device): If the right ventricle is functioning adequately.
* ECMO (Extracorporeal Membrane Oxygenation): A temporary, short-term measure (usually days) for acute stabilization.
* Inotropic Support: High-dose medication (e.g., Milrinone, Dobutamine) for patients who are not surgical candidates.
* Palliative Care/Hospice: For patients who are not candidates for transplant or mechanical support due to comorbidities.

8. Frequently Asked Questions (FAQ)

1. Can a patient live indefinitely with a Total Artificial Heart?
The TAH is currently FDA-approved primarily as a bridge to transplant. While some patients have lived on the device for several years, it is intended to be a temporary solution until a human donor heart becomes available.

2. Does the patient have a heartbeat with a TAH?
Yes. Because the TAH is a pulsatile device, it physically ejects blood in a way that mimics a natural heart, resulting in a palpable pulse.

3. What happens if the power to the external driver fails?
The external drivers have backup battery systems. Furthermore, patients are trained to carry a "backup" driver at all times.

4. Can a patient with a TAH take a shower?
Yes, but it requires specific protocols, including covering the driveline exit sites with sterile waterproof dressings. Swimming, however, is strictly prohibited.

5. How is the TAH different from a heart transplant?
A transplant replaces the heart with a biological organ. A TAH replaces the heart with a mechanical device that requires an external power source and constant anticoagulation.

6. Are there different sizes of TAH?
Yes, the SynCardia TAH comes in 70cc and 50cc models to accommodate different chest cavity sizes, particularly for women and pediatric patients.

7. What is the most common cause of death while on TAH support?
Infection and neurological events (stroke) remain the most significant challenges in the management of these patients.

8. Can a patient go home with a TAH?
Yes. With the "Freedom" portable driver, stable patients can be discharged home while awaiting a transplant, significantly improving their quality of life.

9. Is the TAH noisy?
The pneumatic pulses produce a rhythmic "thumping" sound. Most patients become accustomed to this sound quickly, and it is usually not audible to others in a normal environment.

10. What is the "fit test"?
This is a pre-operative imaging protocol where surgeons use 3D modeling to ensure that the artificial ventricles will fit within the patient's pericardial space without compressing surrounding structures like the lungs or spine.

9. Conclusion

The Total Artificial Heart remains a monumental achievement in medical engineering. By providing a reliable, pulsatile, and high-flow solution for the most critically ill cardiac patients, it has transformed the landscape of end-stage heart failure. While the device carries inherent risks—most notably regarding anticoagulation and infection—the ability to bridge a patient from the brink of death to a successful transplant makes it an indispensable tool in the modern cardiothoracic surgeon's armamentarium. Continued refinement in miniaturization and battery technology promises to further improve the reliability and mobility of these life-saving devices in the coming decade.